目的 系統(tǒng)評價蘇黃止咳膠囊治療感冒后咳嗽的療效和安全性。方法 檢索2007年1月-2015年6月,萬方數(shù)據(jù)庫、中國知識網(wǎng)(CNKI)全文數(shù)據(jù)庫、維普數(shù)據(jù)庫(VIP)及中國生物醫(yī)學光盤數(shù)據(jù)庫中有關蘇黃止咳膠囊治療感冒后咳嗽的臨床隨機對照研究。采用RevMan 5.0軟件對納入的文獻進行定量綜合分析。結(jié)果 檢索到42篇文獻,按照納入和排除標準,最終入選9篇;Meta分析提示,試驗組(蘇黃止咳膠囊組)治療感冒后咳嗽的臨床療效[愈顯率OR=3.15,95%CI為2.33~4.26,P<0.00001;痊愈率OR=12.30,95%CI為1.64~3.25,P<0.00001;有效率OR=4.65,95%CI為3.10~6.98,P<0.00001]與對照組相比有統(tǒng)計學意義;不良反應發(fā)生率[OR=1.09,95%CI為0.29~4.14,P>0.05]與對照組比較無統(tǒng)計學意義。結(jié)論 蘇黃止咳膠囊治療感冒后咳嗽的臨床療效好,不良反應少。

Objective To evaluate the efficacy and safety of Suhuang Zhike Capsule (SZC) in the treatment of post-cold cough. Methods Computer retrieval of Wanfang, CNKI, VIP, and CBM on SZC in the treatment of post-cold cough clinical randomized controlled study (RCTs). Reaching time from January 2007 to June 2015. The control study was carried out by RevMan5.0 software. Results Totally 42 papers were preliminary retrieved in strict accordance with the inclusion and exclusion criteria, nine papers were finally selected. Meta-analysis suggested that the clinical efficacies of experimental groups (SZC groups) in the treatment of post-cold cough were as follows:[healing rate OR=3.15, 95%CI 2.33-4.26, P<0.00001; cure rate OR=12.30, 95%CI 1.64-3.25, P<0.00001; effective rate OR=4.65, 95%CI 3.10-6.98, P<0.00001]. Compared with the control group, there was statistical significance. Incidence of adverse reactions[OR=1.09, 95%CI:0.29-4.14, P>0.05], compared with the control group, there was no statistical significance. Conclusion The clinical efficacy of SZC in the treatment of post-cold cough clinical effect is good, and the adverse reaction is little.

重慶市社會事業(yè)與民生保障科技創(chuàng)新專項(cstc2015shmszx120073);重慶市萬州區(qū)科技計劃項目(201403055);重慶市萬州區(qū)科委科技資助項目(201503008)